PR
RVMD icon

PSP Research’s Revolution Medicines RVMD Stock Holding History

PSP Research’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
+1,200
New +$175K 0.12% 63
2026
Q1 		– Sell
-6,872
Closed -$547K – 96
2025
Q4 		$547K Buy
+6,872
New +$451K 0.48% 13

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

PSP Research's RVMD Position: Q2 2026 in Review

PSP Research opened a new position in Revolution Medicines (RVMD) in Q2 2026: 1,200 shares worth $225K. The stake represents 0.12% of the portfolio and ranks #63 among its holdings. This is a return to the name: PSP Research previously reported a position in RVMD as recently as Q4 2025.

PSP Research first reported a position in RVMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $547K in Q4 2025. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • PSP Research held 1,200 shares of Revolution Medicines worth $225K as of Q2 2026.
  • Revolution Medicines was a new PSP Research position in Q2 2026.
  • Revolution Medicines made up 0.12% of PSP Research's portfolio in Q2 2026, its #63 holding.
  • PSP Research first reported a position in Revolution Medicines in Q4 2025 and has held it in 2 quarters since.
  • PSP Research's Revolution Medicines position peaked at $547K in Q4 2025.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.